AZD4831 placebo
Sponsors
Astrazeneca AB, AstraZeneca
Conditions
"Non-Alcoholic Steatohepatatis (NASH) is the progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD)with a prevalence of approximately 2% to 3% of the general population. Non-alcoholic steatohepatitis can lead to cirrhosis and its complicationsCardiovascular DiseaseNASH is frequently associated with a hyperinsulinemic or insulin resistant stateT2DMand dyslipidemia. Pathophysiologicallyand end stage liver disease.
Non-alcoholic steatohepatitis is defined histologically as a multicomponent condition
composed of hepatic steatosisand hepatocyte ballooning in varying
proportions. NASH differs from steatosis alone by the presence of hepatic cell inflammation and injury in response to lipotoxic intermediates that are accumulated and metabolized in the steatotic liver. NASH is closely associated with metabolic risk factors including obesityhepatocellular carcinoma